Thus, we first confirmed that TGF-β1 treatment was able to enhance the ovarian cancer cell EMT in vitro by assessing the tumor cell morphology and expression of EMT markers (E-cadherin and vimentin). The gene discussed is VIM; the disease is neoplasm.